JP2014076062A5 - - Google Patents

Download PDF

Info

Publication number
JP2014076062A5
JP2014076062A5 JP2013268626A JP2013268626A JP2014076062A5 JP 2014076062 A5 JP2014076062 A5 JP 2014076062A5 JP 2013268626 A JP2013268626 A JP 2013268626A JP 2013268626 A JP2013268626 A JP 2013268626A JP 2014076062 A5 JP2014076062 A5 JP 2014076062A5
Authority
JP
Japan
Prior art keywords
antibody
seq
heavy chain
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013268626A
Other languages
English (en)
Japanese (ja)
Other versions
JP5933517B2 (ja
JP2014076062A (ja
Filing date
Publication date
Priority claimed from PCT/AU2011/000155 external-priority patent/WO2011100786A1/en
Application filed filed Critical
Publication of JP2014076062A publication Critical patent/JP2014076062A/ja
Publication of JP2014076062A5 publication Critical patent/JP2014076062A5/ja
Application granted granted Critical
Publication of JP5933517B2 publication Critical patent/JP5933517B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013268626A 2010-08-17 2013-12-26 ヒト化抗インターロイキン３レセプターα鎖抗体 Active JP5933517B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37448910P 2010-08-17 2010-08-17
US61/374,489 2010-08-17
PCT/AU2011/000155 WO2011100786A1 (en) 2010-02-17 2011-02-17 Compositions and methods for targeting type 1 interferon producing cells
AUPCT/AU2011/000155 2011-02-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013524306A Division JP5524418B2 (ja) 2010-08-17 2011-08-17 ヒト化抗インターロイキン３レセプターα鎖抗体

Publications (3)

Publication Number Publication Date
JP2014076062A JP2014076062A (ja) 2014-05-01
JP2014076062A5 true JP2014076062A5 (enExample) 2014-09-18
JP5933517B2 JP5933517B2 (ja) 2016-06-08

Family

ID=45604615

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013524306A Active JP5524418B2 (ja) 2010-08-17 2011-08-17 ヒト化抗インターロイキン３レセプターα鎖抗体
JP2013268626A Active JP5933517B2 (ja) 2010-08-17 2013-12-26 ヒト化抗インターロイキン３レセプターα鎖抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013524306A Active JP5524418B2 (ja) 2010-08-17 2011-08-17 ヒト化抗インターロイキン３レセプターα鎖抗体

Country Status (13)

Country Link
US (3) US8569461B2 (enExample)
EP (2) EP2606069B1 (enExample)
JP (2) JP5524418B2 (enExample)
KR (1) KR101347688B1 (enExample)
CN (1) CN103025761B (enExample)
CA (1) CA2805176C (enExample)
DK (1) DK2606069T3 (enExample)
ES (1) ES2506340T3 (enExample)
GB (1) GB2488091B (enExample)
IL (1) IL225631A (enExample)
NZ (1) NZ604510A (enExample)
PL (1) PL2606069T3 (enExample)
WO (1) WO2012021934A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10611835B2 (en) * 2008-07-10 2020-04-07 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
PT2426148E (pt) 2009-04-27 2015-10-26 Kyowa Hakko Kirin Co Ltd Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
EP4053162A1 (en) * 2012-05-18 2022-09-07 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
US20160046718A1 (en) * 2013-03-14 2016-02-18 Csl Limited Agents that neutralize il-3 signalling and uses thereof
WO2014138805A1 (en) * 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
MY191964A (en) * 2015-01-23 2022-07-21 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
EP3310440A1 (de) 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
CA2990398A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies
EP3842459A1 (en) * 2015-06-29 2021-06-30 ImmunoGen, Inc. Anti-cd123 antibodies and conjugates and derivatives thereof
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
JP7022707B2 (ja) * 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
US11242400B2 (en) 2016-09-21 2022-02-08 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
TWI843344B (zh) 2017-06-02 2024-05-21 美商輝瑞大藥廠 對ｆｌｔ３具特異性之抗體及其用途
CA3089754A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2020183245A2 (en) * 2019-03-11 2020-09-17 Janssen Pharmaceutica Nv ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES
AU2020269268A1 (en) 2019-05-04 2021-11-11 Inhibrx Biosciences, Inc. CD123-binding polypeptides and uses thereof
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2022056192A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
JP7623497B2 (ja) 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
EP4380693A1 (en) * 2021-08-06 2024-06-12 Universität Basel Discernible cell surface protein variants for use in cell therapy
TW202413419A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
EP4296280A1 (en) * 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)
TW202434305A (zh) 2022-11-17 2024-09-01 德商溫瑟克斯製藥公司 於腫瘤微環境中可裂解之抗體-藥物結合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1997024373A1 (en) * 1995-12-29 1997-07-10 Medvet Science Pty. Limited Monoclonal antibody antagonists to haemopoietic growth factors
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
ES2292682T3 (es) 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
KR100627856B1 (ko) * 2004-06-28 2006-09-25 에스케이 텔레콤주식회사 착신측 교환기를 이용하여 멀티미디어 링백톤 서비스를제공하는 방법 및 시스템
RU2412200C2 (ru) * 2004-11-12 2011-02-20 Ксенкор, Инк. Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
JP2008528668A (ja) 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
RU2008110060A (ru) 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Сконструированные антитела с каркасными участками приматов нового света
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN101896200A (zh) * 2007-12-06 2010-11-24 Csl有限公司 抑制白血病干细胞的方法
CA2736904A1 (en) * 2008-09-26 2010-04-01 Wyeth Llc Compatible display vector systems
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
PT2426148E (pt) * 2009-04-27 2015-10-26 Kyowa Hakko Kirin Co Ltd Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2014076062A5 (enExample)
JP2013537418A5 (enExample)
US12448423B2 (en) Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains
CN107580500B (zh) 抗pvrig抗体和使用方法
JP2020189869A (ja) 抗ｌａｇ３抗体およびその使用
JP2020513786A5 (enExample)
JP2016538830A5 (enExample)
US12029778B2 (en) Interleukin-18 mimics and methods of use
JP2009521909A5 (enExample)
JP2017529838A5 (enExample)
JP2013165711A5 (enExample)
JP2009502171A5 (enExample)
JP2018500014A5 (enExample)
JP2011514150A5 (enExample)
JP2014511179A5 (enExample)
JP2015517470A5 (enExample)
JP2008542278A5 (enExample)
JP2015535691A5 (enExample)
JP2016506388A5 (enExample)
AU2020283817A1 (en) TIGIT and PD-1/TIGIT-binding molecules
JP2014526898A5 (enExample)
JP2020527332A5 (enExample)
JP2017506669A5 (ja) 膠芽腫の治療に使用するための組成物及びその使用
EP2970447A1 (en) Pan-elr+ cxc chemokine antibodies
JP2016538297A5 (enExample)